Bull Case

Clinical adoption and reimbursement progress accelerate revenue growth, lifting MYO above smaller neuromuscular peers that remain earlier in commercialization.

Operating leverage from higher procedure volumes and a richer installed base narrows losses, improving margins faster than peers with less scalable sales models.

Expanded evidence in additional indications supports broader physician uptake, increasing demand durability versus peers concentrated in a single use case.

Improved cash generation and reduced financing dependence lower dilution risk, strengthening forward structure relative to peers with weaker balance sheets.

Base Case

Commercial growth continues but remains uneven, keeping MYO ahead of pre-scale peers while still below larger medtech platforms with broader distribution.

Gross profit expansion offsets only part of operating expense growth, so margins improve gradually rather than reaching peer-leading levels.

Adoption in core procedures remains the main driver, but reimbursement and training friction cap the pace of penetration versus better-established competitors.

Liquidity remains manageable but not abundant, leaving MYO more resilient than highly levered peers yet still dependent on execution to avoid dilution.

Bear Case

Slower-than-expected adoption stalls revenue growth, leaving MYO behind peers that convert clinical interest into recurring procedure volumes more quickly.

Persistent operating losses and weak cash conversion force additional capital raises, pressuring margins and per-share economics versus better-funded competitors.

Reimbursement delays or limited physician utilization constrain demand, reducing the addressable market relative to peers with clearer coverage pathways.

Balance-sheet stress rises if financing conditions tighten, making MYO more vulnerable than peers with stronger cash buffers and positive operating cash flow.

Overall Score

MYO’s forward profile is balanced between commercialization upside and execution risk, with outcomes likely to remain below stronger scaled peers unless adoption and margin leverage improve.